Company Encyclopedia
View More
name
Voyager Therap
VYGR.US
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. The company’s lead product candidate is VY7523, an anti-tau antibody program for the treatment of alzheimer’s disease (AD). Its product pipeline includes VY1706, a tau silencing gene therapy in preclinical trial for the treatment of alzheimer’s disease; SOD1 silencing gene therapy program for treating amyotrophic lateral sclerosis in preclinical trial; and vectorized anti-amyloid antibody early research program for the treatment of AD in preclinical trial. The company is also developing VY-FXN01 for treating friedreich’s ataxia; and GBA1 gene replacement program to treat parkinson’s disease.
1.946 T
VYGR.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
BiotechnologyIndustry
Industry Ranking247/394
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-46.09%E
    • Profit Margin-404.85%E
    • Gross Margin-168.36%E
  • Growth ScoreE
    • Revenue YoY-80.88%E
    • Net Profit YoY-589.88%E
    • Total Assets YoY-32.33%E
    • Net Assets YoY-33.45%E
  • Cash ScoreE
    • Cash Flow Margin-24.70%D
    • OCF YoY-80.88%E
  • Operating ScoreE
    • Turnover0.09E
  • Debt ScoreB
    • Gearing Ratio23.75%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    H.C. Wainwright Sticks to Their Buy Rating for Voyager Therapeutics (VYGR)

    H.C. Wainwright's Patrick Trucchio reiterated a Buy rating for Voyager Therapeutics with a $25.00 price target. Shares closed at $4.23. Trucchio, a 5-star analyst, has a 27.1% average return and 51.33% success rate. The consensus rating for Voyager Therapeutics is Strong Buy with a $14.00 average price target.

    Tip Ranks·
    US
    VYGR
    0.00%
    Tip Ranks·
    US
    VYGR
    0.00%

    Voyager Therapeutics (NASDAQ:VYGR) Shares Pass Below Fifty Day Moving Average - Here's What Happened

    Voyager Therapeutics shares fell below the 50-day moving average, trading as low as $3.91. Analysts have mixed ratings, with some upgrading to 'hold' and others maintaining 'buy' or 'sell'. The company reported better-than-expected earnings, with revenue of $11.15 million. Insider trading and hedge fund activities are noted, with 48.03% of stock owned by institutions. Voyager focuses on gene therapy for neurological diseases.

    Market Beat·
    US
    VYGR
    0.00%
    Market Beat·
    US
    VYGR
    0.00%

    Voyager Therapeutics (VYGR) Receives a Buy from Wells Fargo

    In a report released today, from Wells Fargo maintained a Buy rating on Voyager Therapeutics, with a price target of $10.00.Meet Your ETF AI Analyst Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow. Voyager Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $14.29.

    Tip Ranks·
    US
    VYGR
    0.00%
    Tip Ranks·
    US
    VYGR
    0.00%

    Voyager Therapeutics (NASDAQ:VYGR) Issues Earnings Results, Beats Expectations By $0.06 EPS

    Voyager Therapeutics (NASDAQ:VYGR) reported earnings of ($0.47) per share, exceeding expectations of ($0.53) by $0.06. The company has a negative return on equity of 37.65% and a negative net margin of 253.49%. Following the earnings report, Voyager's stock rose 30% to $4.26. Institutional investors hold 48.03% of the stock, with recent modifications in holdings by major firms. Analysts have mixed ratings, with an average target price of $12.96, indicating a "Moderate Buy" sentiment.

    Market Beat·
    US
    VYGR
    0.00%
    Market Beat·
    US
    VYGR
    0.00%

    Voyager Therapeutics: Strong Financial Position and Promising Pipeline Justify Buy Rating

    TD Cowen analyst Phil Nadeau has maintained a Buy rating on Voyager Therapeutics (VYGR) stock, citing the company's strong financial position with $229 million in cash, ensuring operations until 2028. The promising Alzheimer’s pipeline, including assets VY7523 and VY1706, is progressing towards key milestones in 2026. Collaborations with Neurocrine Biosciences also indicate growth potential. Leerink Partners echoed this sentiment with a Buy rating and a $11.00 price target.

    Tip Ranks·
    US
    VYGR
    0.00%
    Tip Ranks·
    US
    VYGR
    0.00%
    © 2025 Longbridge｜Disclaimer